Let's focus on getting answers to questions and identifying liabilities. At stake here are the lives of tens of thousands of children.
Watch Rappler’s evening newscast with Acor Arceo
(UPDATED) The drug regulatory agency also directs pharma giant Sanofi to 'conduct an information dissemination campaign through advisories, Dear Doctor letters, and patient fora'
Will Sanofi shoulder the costs of individuals who might contract severe dengue after receiving the vaccine? The company only says it is collaborating with the Department of Health.
(3rd UPDATE) However, when a person gets the vaccine after he has had an infection, the effectivity of the vaccine increases by up to 6 years, says Dr Ng Su Peing, global medical head of Sanofi
'There are countless number of lives that have been saved from vaccine-preventable diseases,' says Health Secretary Francisco Duque III
(UPDATED) The Philippine government spent P3.5 billion on the mass immunization program, funded by sin tax revenues
(2nd UPDATE) Health Secretary Francisco Duque III temporarily halts the program after Dengvaxia maker Sanofi Pasteur said its product poses higher risks to people without prior infection
(UPDATED) Here are the key moments in the controversial implementation of the dengue immunization program by the Department of Health
After Sanofi Pasteur's advisory on Dengvaxia, Dr Anthony Leachon says students who already got their dengue shots from DOH will live with the possibility of getting severe dengue 'for the rest of their lives'
Philippine Health Secretary Francisco Duque III says the 'safety of Filipino children' is the prime consideration as health officials meet on the implications of Sanofi Pasteur's advisory on Dengvaxia
The Philippine Council for Health Research and Development says it approved only the technical aspects of the clinical trials of ActRx TriAct for dengue treatment
President Benigno Aquino III accuses a pharmaceutical company of overpricing leptospirosis drugs by 750 amid widespread flooding